Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Brett Case

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Annual Review of Immunology|December 20, 2024
SARS-CoV-2: The Interplay Between Evolution and Host ImmunityJames Brett Case, Shilpi Jain, Mehul S Suthar, et al.
Journal of Virology|June 3, 2016
Mutagenesis of S-Adenosyl-l-Methionine-Binding Residues in Coronavirus nsp14 N7-Methyltransferase Demonstrates Differing Requirements for Genome Translation and Resistance to Innate ImmunityJames Brett Case, Alison W Ashbrook, Terence S Dermody, et al.
Virology|March 6, 2021
On the road to ending the COVID-19 pandemic: Are we there yet?James Brett Case, Emma S Winkler, John M Errico, et al.
Virology|August 26, 2020
Growth, detection, quantification, and inactivation of SARS-CoV-2James Brett Case, Adam L Bailey, Arthur S Kim, et al.
Mbio|November 9, 2017
Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating MutationsKevin W Graepel, Xiaotao Lu, James Brett Case, et al.
Journal of Virology|April 10, 2015
Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelityEverett Clinton Smith, James Brett Case, Hervé Blanc, et al.
Journal of Virology|October 20, 2017
Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate ImmunityJames Brett Case, Yize Li, Ruth Elliott, et al.
Journal of Virology|October 20, 2021
SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In MiceEmma S Winkler, Rita E Chen, Fahmida Alam, et al.
Clinical Chemistry|September 7, 2020
Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological AssaysMei San Tang, James Brett Case, Caroline E Franks, et al.
Cell Reports|May 26, 2022
Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodiesShane Miersch, Nitin Sharma, Reza Saberianfar, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Annual Review of Immunology|December 20, 2024
SARS-CoV-2: The Interplay Between Evolution and Host ImmunityJames Brett Case, Shilpi Jain, Mehul S Suthar, et al.
Journal of Virology|June 3, 2016
Mutagenesis of S-Adenosyl-l-Methionine-Binding Residues in Coronavirus nsp14 N7-Methyltransferase Demonstrates Differing Requirements for Genome Translation and Resistance to Innate ImmunityJames Brett Case, Alison W Ashbrook, Terence S Dermody, et al.
Virology|March 6, 2021
On the road to ending the COVID-19 pandemic: Are we there yet?James Brett Case, Emma S Winkler, John M Errico, et al.
Virology|August 26, 2020
Growth, detection, quantification, and inactivation of SARS-CoV-2James Brett Case, Adam L Bailey, Arthur S Kim, et al.
Mbio|November 9, 2017
Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating MutationsKevin W Graepel, Xiaotao Lu, James Brett Case, et al.
Journal of Virology|April 10, 2015
Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelityEverett Clinton Smith, James Brett Case, Hervé Blanc, et al.
Journal of Virology|October 20, 2017
Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate ImmunityJames Brett Case, Yize Li, Ruth Elliott, et al.
Journal of Virology|October 20, 2021
SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In MiceEmma S Winkler, Rita E Chen, Fahmida Alam, et al.
Clinical Chemistry|September 7, 2020
Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological AssaysMei San Tang, James Brett Case, Caroline E Franks, et al.
Cell Reports|May 26, 2022
Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodiesShane Miersch, Nitin Sharma, Reza Saberianfar, et al.
Pageof 9